Actively Recruiting

Phase 3
Age: 10Months - 11Months
All Genders
NCT03198702

Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy

Led by University Hospital, Brest · Updated on 2026-03-20

62

Participants Needed

7

Research Sites

471 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In children population with obstetrical brachial plexus palsy (OBPP), shoulder musculoskeletal deformity is the main cause of morbidity, with a loss of range of shoulder motion, pain and a reduction in social participation. Some uncontrolled studies shows that early injections of botulinum toxin (BTI) in the internal shoulder rotator muscles (which cause the deformity) are one of the most promising treatment for the prevention of bony deformity. The main objective of this study will be the evaluation of the effectiveness of BTI in the internal shoulder rotator muscles at the age of 12 months in preventing an increase in posterior subluxation of the glenohumeral joint in babies with OBPP (evaluated at the ages of 11 months and 18 months), compared to the Sham group.

CONDITIONS

Official Title

Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy

Who Can Participate

Age: 10Months - 11Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female babies with unilateral OBPP
  • Age between 10 and 11 months
  • Presenting one of 2 risk factors for posterior subluxation of the humeral head (10° less passive external ROM of the affected shoulder compared with the contralateral shoulder and/or a score strictly less than 6 on the AMS for shoulder external rotation and abduction, elbow flexion or supination)
  • Signature of the consent form by (the) parent(s) over the age of majority
Not Eligible

You will not qualify if you...

  • Bilateral OBPP
  • Microsurgery or secondary muscle surgery planned between 12 and 18 months of age
  • Contraindications to the use of botulinum toxin
  • Contraindications to MRI
  • MRI not possible in the Paediatric Day Hospital setting because of contraindications to the sedation protocol or due to organisational constraints
  • Parents inapt to provide consent for the participation of their child
  • Parents under the age of 18 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

CHRU Brest

Brest, France, 29609

Actively Recruiting

2

Institut Régionnal de Réadaptation Centre de Réadaptation pour enfant

Flavigny-sur-Moselle, France, 54630

Not Yet Recruiting

3

ESEAN (Etablissement de Santé pour Enfants et Adolescents de la région Nantaise)

Nantes, France

Not Yet Recruiting

4

CHU Nîmes

Nîmes, France, 30029

Actively Recruiting

5

CHU Rennes

Rennes, France, 35033

Actively Recruiting

6

CHU St Etienne

Saint-Etienne, France, 42055

Not Yet Recruiting

7

Hôpital national de saint maurice

Saint-Maurice, France, 94410

Actively Recruiting

Loading map...

Research Team

S

Sylvain Brochard, Pr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here